Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET

Company Participants

Robert Andrade - Chief Financial Officer
Jeff Hackman - Chief Executive Officer and Director

Conference Call Participants

Chase Knickerbocker - Craig-Hallum
Raghuram Selvaraju - H.C. Wainwright

Operator

Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2024 Earnings and Corporate Update Conference Call. At this time, all participants are in listen-only mode. Later we will conduct question-and-answer session and instructions in how to participate will begin at that time. [Operator Instructions]. As a reminder, today's conference call is being recorded.

Now I would like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade.

Robert Andrade

Thank you, operator, and good morning, everyone. We appreciate you joining us today for Fennec Pharmaceuticals third quarter 2024 earnings conference call, during which we will review our financial results as well as provide a general business update.

Joining me from Fennec this morning is our Chief Executive Officer and Board member, Jeff Hackman. As a reminder, Jeff joined Fennec on August 5th and in just a few short months has made significant progress in positioning the company for near-term and future growth and sustainability.

Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the U.S. Securities and Exchange Commission.

In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on Fennec's website, www.fennecpharma.com, where it will be available for the next 30 days.

Now with that behind us, I will now turn the call over to Jeff Hackman. Jeff?

Jeff Hackman

Thank you, Robert, and good morning, everyone. This morning, I'm going to discuss the recent progress that we've been making, along with some key developments, including developments around market expansion, our academic endorsements, new demographic interest, our educational investments, our operational efficiencies, the strengthening of our leadership and most importantly our execution, all of which will drive meaningful growth in the quarters ahead.